Drugs

QUIZ: Are you on top of recent studies that could affect your practice?
Patients, Experience, Evidence, Research (PEER), a Canadian evidence-based medicine group, has released its annual list of the past year’s top studies relevant to primary care. They’re on top of the latest research. Are you? Find out here!
Canadian pancreatic cancer specialists expect to open clinical trials on pill that doubled survival time
Dr. Jennifer Knox, medical director of the pancreatic cancer clinic at Princess Margaret Cancer Centre in Toronto, said she hopes to start a clinical trial of the experimental medication daraxonrasib and other related drugs at her centre in the coming months.

POP QUIZ: Antihypertensive discontinuation due to adverse effects

A recent JAMA network meta-analysis identified the top five best-tolerated drug classes and combinations, in terms of lowest treatment discontinuation rates due to adverse events in short-term trials.
Canadian pancreatic cancer specialist expects to open clinical trials on pill that doubled survival time

The drug targets a mutation found in more than 90% of pancreatic cancers.
‘Having treated pancreatic cancer for 16 years, I actually started crying’: Experimental pill promises new hope for deadly pancreatic cancer

‘While not curing the cancer, it is a very large step forward,’ said Dr. Zev Wainberg, of the University of California, Los Angeles, who helped lead the study.
Do antihypertensive classes differ in adverse effect rates leading to discontinuation?

Study identifies which of the five major antihypertensive drug classes is associated with the lowest rates of medication discontinuation due to adverse events.
Minor ailment counselling tool: Nicotine replacement pouches
Drug News—May 2026

Get the info you need on these new products, generics, indications and more in our full drug news roundup for May.
Some IBS drugs may do more harm than good, new study suggests

Researchers say medications commonly recommended for irritable bowel syndrome should be evaluated not just for symptom relief, but for how often side effects lead patients to stop treatment.
NEW DRUG: Loqtorzi for nasopharyngeal carcinoma

Get the info you need on this new product, part of our drug news roundup for June.

QUIZ: Are you on top of recent studies that could affect your practice?

Canadian pancreatic cancer specialists expect to open clinical trials on pill that doubled survival time

POP QUIZ: Antihypertensive discontinuation due to adverse effects

Canadian pancreatic cancer specialist expects to open clinical trials on pill that doubled survival time

‘Having treated pancreatic cancer for 16 years, I actually started crying’: Experimental pill promises new hope for deadly pancreatic cancer

Do antihypertensive classes differ in adverse effect rates leading to discontinuation?

Minor ailment counselling tool: Nicotine replacement pouches

Drug News—May 2026

Some IBS drugs may do more harm than good, new study suggests

NEW DRUG: Loqtorzi for nasopharyngeal carcinoma